
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.23 | 0.750407830343 | 30.65 | 31.4964 | 29.73 | 1334193 | 30.97786913 | CS |
4 | 1.97 | 6.81425112418 | 28.91 | 34.58 | 28.44 | 1710120 | 32.15092379 | CS |
12 | -4.31 | -12.2477976698 | 35.19 | 35.78 | 27.24 | 2086026 | 31.33337976 | CS |
26 | 6.14 | 24.8181083266 | 24.74 | 36.84 | 21.11 | 2965534 | 27.68259337 | CS |
52 | 17.87 | 137.355880092 | 13.01 | 36.84 | 12.84 | 3137302 | 22.24070752 | CS |
156 | 20.54 | 198.646034816 | 10.34 | 36.84 | 3.48 | 3844690 | 15.5340399 | CS |
260 | 15.11 | 95.8148383006 | 15.77 | 56.74 | 3.48 | 3025945 | 18.18950647 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관